AG Mednet provides technology solutions for clinical trial adjudication and imaging to global contract research organizations (CROs).
Under its renewed partnership with Median – which provides medical image analysis and management services for global oncology trials – AG Mednet will support Median’s portfolio of trials, including its “large programs” in China, according to the company.
Median will use AG Mednet's electronic transfer solutions to manage images and enable the extraction of imaging biomarkers.
Abraham Gutman, president and CEO of AG Mednet, said China represents a significant percentage of AG Mednet users for two reasons: "Global trials are finding significant numbers of subjects there to test biologics, drugs and devices.
"Additionally, there is a clear push on the part of China to become competitive in pharma, both in the development of new therapies as well as testing more traditional Chinese medicine applications. China continues to produce highly skilled scientists and doctors."
Gutman told us, "Median has recognized that a presence in-country, staffed by local talent, allows it to service the market in more efficient and productive way. It is for this reason that AG Mednet has become their tool of choice, since we have the most robust ability to collect images globally, including in China, and deliver them to China in a continuous and reliable manner."
